Johnson & Johnson (JNJ) Shares Bought by First National Trust Co

First National Trust Co grew its holdings in Johnson & Johnson (NYSE:JNJ) by 2.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 126,340 shares of the company’s stock after buying an additional 3,012 shares during the quarter. Johnson & Johnson comprises approximately 1.7% of First National Trust Co’s holdings, making the stock its 10th largest holding. First National Trust Co’s holdings in Johnson & Johnson were worth $15,330,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. E&G Advisors LP grew its position in shares of Johnson & Johnson by 6.0% in the 2nd quarter. E&G Advisors LP now owns 8,876 shares of the company’s stock worth $1,077,000 after buying an additional 500 shares during the last quarter. Telos Capital Management Inc. grew its position in shares of Johnson & Johnson by 6.4% in the 2nd quarter. Telos Capital Management Inc. now owns 25,036 shares of the company’s stock worth $3,038,000 after buying an additional 1,495 shares during the last quarter. Dimension Capital Management LLC grew its position in shares of Johnson & Johnson by 106.3% in the 2nd quarter. Dimension Capital Management LLC now owns 7,340 shares of the company’s stock worth $891,000 after buying an additional 3,782 shares during the last quarter. Pinnacle Financial Partners Inc. grew its position in shares of Johnson & Johnson by 13.9% in the 2nd quarter. Pinnacle Financial Partners Inc. now owns 98,896 shares of the company’s stock worth $12,001,000 after buying an additional 12,044 shares during the last quarter. Finally, Glenview State Bank Trust DEPT. grew its position in shares of Johnson & Johnson by 2.3% in the 2nd quarter. Glenview State Bank Trust DEPT. now owns 72,884 shares of the company’s stock worth $8,843,000 after buying an additional 1,625 shares during the last quarter. Institutional investors and hedge funds own 66.70% of the company’s stock.

A number of research analysts have recently issued reports on the stock. Credit Suisse Group set a $149.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, October 14th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. Raymond James lifted their price objective on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $142.54.

NYSE:JNJ opened at $140.68 on Friday. The company has a market cap of $377.43 billion, a price-to-earnings ratio of 17.70, a P/E/G ratio of 2.20 and a beta of 0.58. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The company has a current ratio of 1.72, a quick ratio of 1.33 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. Johnson & Johnson’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 EPS. On average, equities research analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.56%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

In other news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply